Intuitive Surgical stock pairs growth with antitrust charge

Published on 11/04/2026 at 16:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Intuitive Surgical stock traded at EUR 425.08 on Lang & Schwarz on Wednesday. Strong procedure growth was offset in reported earnings by a proposed antitrust settlement.

Growth, Charge and Outlook

Third-quarter revenue increased 22 percent, while da Vinci and Ion procedures continued to expand.
A proposed antitrust settlement reduced GAAP earnings but does not include an admission of liability or wrongdoing.
Management expects 2026 da Vinci procedure growth near the midpoint of its 14 to 15 percent range.

Intuitive Surgical, US46120E6023, Illustration mit AI erstellt.

Intuitive Surgical delivered strong operating growth in the third quarter, while a proposed antitrust settlement weighed heavily on reported earnings. The company disclosed the results in its earnings release for the quarter ended September 30, 2026, published on October 20.

The release from Intuitive Surgical showed a 22 percent increase in revenue to USD 3.05 billion. Worldwide procedures across the da Vinci and Ion platforms rose approximately 15 percent year over year. Da Vinci procedures increased about 14 percent and Ion procedures about 31 percent.

Operational scale keeps expanding

The company placed 546 da Vinci surgical systems during the quarter, compared with 427 a year earlier. The placements included 315 da Vinci 5 systems, versus 240 in the prior-year period. The da Vinci installed base reached 12,094 systems at September 30, up 12 percent year over year, while the Ion installed base rose 21 percent to 1,152 systems.

Instruments and accessories revenue increased 18 percent to USD 1.80 billion, supported by procedure growth. Systems revenue rose to USD 769 million from USD 590 million. The recurring instruments business and the expanding installed base remain important indicators for future utilization and revenue growth.

Legal charge clouds reported profit

Intuitive recorded a USD 450 million pre-tax charge tied to a proposed settlement of previously disclosed antitrust litigation. The agreement includes a one-time payment and mutually agreed injunctive relief, but remains subject to preliminary and final court approval. The company said it admitted neither liability nor wrongdoing.

GAAP net income attributable to Intuitive fell to USD 523 million, or USD 1.49 per diluted share, from USD 704 million, or USD 1.95, a year earlier. On a non-GAAP basis, net income rose to USD 1.05 billion, or USD 3.00 per diluted share, from USD 867 million, or USD 2.40.

Outlook remains within range

Management expects worldwide da Vinci procedure growth of approximately 14 to 15 percent in 2026 and expects growth to land closer to the midpoint. The company also projects non-GAAP operating expense growth of 11 to 13 percent and a non-GAAP gross margin of 68.7 to 69.3 percent.

At Lang & Schwarz, Intuitive Surgical stock traded at 425.08 euros at 16:34 CET on Wednesday, November 4, 2026. Investors can follow the real-time quote of Intuitive Surgical stock.